Source comparison
Best ARA-290 Dosage for Neuroprotection: Protocol Comparison
Below is a synthesis of published dosing protocols from peer-reviewed neuroprotection studies, organized by research model and observed endpoint. Diabetic Polyneuropathy (Type 2 DM) 4 mg subcutaneous 3× weekly × 12 weeks Intraepidermal nerve fibre density (IEN
This comparison does not assign a generated winner or score.
- Below is a synthesis of published dosing protocols from peer-reviewed neuroprotection studies, organized by research model and observed endpoint.
- Diabetic Polyneuropathy (Type 2 DM)
- 4 mg subcutaneous
- 3× weekly × 12 weeks
- Intraepidermal nerve fibre density (IENFD)
- +29% IENFD vs baseline; no change in placebo arm
- Robust histological improvement; dose replication recommended
- Chemotherapy-Induced Peripheral Neuropathy (CIPN)
- 2 mg subcutaneous
- 3× weekly × 8 weeks
- Mechanical allodynia threshold (von Frey)
- Threshold increased 40% vs vehicle; effect plateaued at week 6
- Effective but suboptimal dose. 4 mg likely superior
- Ischemic Stroke (MCAO model, rodent)
- 1 mg/kg IP (≈5 mg human-equivalent)
- Single dose at 3 hours post-occlusion
- Infarct volume (TTC staining)
- 35% reduction in cortical infarct vs saline
- Acute neuroprotection confirmed; chronic dosing unexplored
- Traumatic Brain Injury (controlled cortical impact)
- 8 mg/kg IP (≈40 mg human-equivalent)
- Daily × 7 days post-injury
- Motor function recovery (rotarod test)
- Improved latency to fall by day 14; no benefit at day 28
- High dose with transient effect; receptor saturation likely
- Sarcoidosis-Associated Small Fibre Neuropathy (Phase 2 trial)
- 3× weekly × 28 days
- Corneal nerve fibre length (CNFL)
- +0.8 mm/mm² vs −0.1 mm/mm² placebo (p=0.03)
- First human trial data; dose clinically validated